News Column

Research Conducted at National Institute of Chemistry Has Provided New Information about Cancer Therapy

February 12, 2014



By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting originating from Ljubljana, Slovenia, by NewsRx correspondents, research stated, "DNA topoisomerases comprise an important family of enzymes that catalyse the induction of topological changes (e.g. relaxation/ supercoiling, catenation/decatenation and knotting/unknotting) in the DNA molecule. These enzymes perform their functions by creating transient either single-stranded or double-stranded breaks in the DNA molecule."

Our news editors obtained a quote from the research from the National Institute of Chemistry, "Due to their ability to modulate the topology of the DNA molecule, DNA topoisomerases play vital roles in replication, transcription, chromosome separation and segregation, and thus represent an important collection of design targets for novel anticancer drugs. The aim of this review is to provide an overview of the development of catalytic inhibitors of the human topoisomerase II? enzyme--an important member of the DNA topoisomerase family--as potential novel anticancer agents. The group of catalytic topoII inhibitors is classified into four types according to their molecular mechanism of action: inhibitors that bind to the ATP binding site, inhibitors that prevent the ATP hydrolysis step and trap the enzyme in a closed clamp, inhibitors that block the DNA cleavage and inhibitors that prevent the enzyme binding to the DNA."

According to the news editors, the research concluded: "One of the important considerations highlighted throughout this review is the structure-based perspective of inhibitor design, giving the reader a medicinal chemist's perspective on this vibrant and active field of drug design research."

For more information on this research see: Recent advances in the development of catalytic inhibitors of human DNA topoisomerase II? as novel anticancer agents. Current Medicinal Chemistry, 2013;20(5):694-709. (Bentham Science Publishers - www.benthamscience.com; Current Medicinal Chemistry - www.benthamscience.com/cmc/index.htm)

The news editors report that additional information may be obtained by contacting B. Pogorel?nik, National Institute of Chemistry, Ljubljana, Slovenia. Additional authors for this research include A. Perdih and T. Solmajer (see also Oncology).

Keywords for this news article include: Europe, Therapy, Slovenia, Oncology, Ljubljana, DNA Research, DNA Topoisomerases, Enzymes and Coenzymes.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools